News - Novartis, Oncology

Filter

Current filters:

NovartisOncology

Popular Filters

1 to 25 of 92 results

$25 million milestone for Incyte on Japanese approval of Jakavi

$25 million milestone for Incyte on Japanese approval of Jakavi

08-07-2014

US biopharma company Incyte says it has earned a $25 million milestone payment from Swiss drug major…

BiotechnologyBusiness FinanceBusiness FinanceFinancialIncyteJakaviJapanMajorMedicineNovartisOncologyRegulationRuxolitinib

Novartis receives fifth Breakthrough Therapy designation with CTL019 for leukemia

Novartis receives fifth Breakthrough Therapy designation with CTL019 for leukemia

08-07-2014

Swiss drug major Novartis has been granted Breakthrough Therapy designation for its leukemia treatment…

CancerCTL019LeukemiaNovartisOncologyPharmaceuticalRefractory acute lymphoblastic leukemiaRegulationUSA

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

UK’s NICE draft guidance backs Novartis’ Glivec for GISTs

27-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Novartis outlines aims to be more profitable and increasingly focused

Novartis outlines aims to be more profitable and increasingly focused

19-06-2014

Swiss drug major Novartis has set out its new focused portfolio at the first Meet Novartis Management…

EuropeManagementNovartisOncologyOphthalmicsPharmaceutical

Doomed future for Tykerb in breast cancer arena, says analyst

Doomed future for Tykerb in breast cancer arena, says analyst

16-06-2014

The future of Tykerb (lapatinib) in the breast cancer market looks bleak, after the combination of GlaxoSmithKline’s…

BiotechnologyGlaxoSmithKlineMarkets & MarketingNovartisOncologyResearchTykerb

Servier inks oncology collaboration with Novartis

20-05-2014

French independent drugmaker Laboratories Servier has signed a strategic global collaboration agreement…

LicensingNovartisOncologyPharmaceuticalServier

Novartis patent settlement on Gleevec with Sun Pharma subsidiary

15-05-2014

The US unit of Swiss drug major Novartis has settled its litigation with the US subsidiary of India’s…

GenericsGleevecNovartisOncologyPatentsSun Pharmaceutical IndustriesUSA

Novartis gains US approval for NSCLC drug candidate Zykadia

Novartis gains US approval for NSCLC drug candidate Zykadia

30-04-2014

The US Food and Drug Administration said late yesterday that it has granted accelerated approval for…

NovartisOncologyPharmaceuticalRegulationUSAZykadia

Transgene seeks partner for TG4010 as Novartis opts out

29-04-2014

There was disappointing news for French biotech firm Transgene today, when it received notification from…

BiotechnologyLicensingNovartisOncologyTransgene

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

Novartis’ ceritinib improves survival in patients with non-small cell lung cancer

Novartis’ ceritinib improves survival in patients with non-small cell lung cancer

27-03-2014

Swiss drug major Novartis has published clinical trial results showing the investigational compound LDK378…

LDK378Northern EuropeNovartisOncologyPharmaceuticalResearch

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

07-03-2014

Swiss pharma major Novartis today announced positive results from a pivotal Phase III trial of Jakavi…

IncyteJakaviNovartisOncologyPharmaceuticalRare diseasesRegulationResearch

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Novartis’ LDE225 met primary endpoint in pivotal trial for advanced basal cell carcinoma

Novartis’ LDE225 met primary endpoint in pivotal trial for advanced basal cell carcinoma

19-02-2014

Swiss drug major Novartis says the pivotal trial of the investigational oral compound LDE225 (sonidegib)…

LDE225NovartisOncologyPharmaceuticalResearchsonidegib

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Cell Therapeutics to reacquire rights to two anti-cancer compounds

13-01-2014

US biotech firm Cell Therapeutics says it has reached an agreement with partner Novartis to reacquire…

BiotechnologyCell TherapeuticsLicensingNovartisOncologyOpaxioPixuvri

Renal cell cancer market to rapidly decline from 2019

Renal cell cancer market to rapidly decline from 2019

24-12-2013

The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly…

AfinitorAvastinBayerFinancialGlaxoSmithKlineInlytaMarkets & MarketingNexavarNorthern EuropeNovartisOncologyPfizerPharmaceuticalRocheSutentToriselUSAVotrient

Oncology most active therapeutic area for Ph II/III R&D

Oncology most active therapeutic area for Ph II/III R&D

25-11-2013

While metabolic drugs account for one-quarter of drugs recently filed for approval or approved, oncology…

NovartisOncologyPharmaceuticalResearch

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

Novartis takes up license for ImmunoGen ADC technology

Novartis takes up license for ImmunoGen ADC technology

11-10-2013

US biotech firm ImmunoGen says that Swiss drug major Novartis has licensed the exclusive right to use…

BiotechnologyImmunoGenLicensingNovartisOncology

Novartis progresses with clinical trials in chronic myeloid leukemia

19-09-2013

Swiss drug major Novartis (NOVN: VX) has released an update on its clinical trial program on evaluating…

EuropeImatinib MesylateNilotinib CapsulesNovartisOncologyPharmaceuticalResearch

New therapies to spur acute myeloid leukemia market growth

27-08-2013

Driven by a boost in new therapies entering the market, as well as an increasing number of acute myeloid…

BiotechnologyCyclacel PharmaceuticalsMarkets & MarketingmidostaurinNovartisOncologyPharmaceuticalsapacitabineSunesis Pharmaceuticalsvosaroxin

1 to 25 of 92 results

Back to top